iBio
IBIO
30 hedge funds and large institutions have $6.4M invested in iBio in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
11% more capital invested
Capital invested by funds: $5.79M → $6.4M (+$612K)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.63% less ownership
Funds ownership: 30.18% → 28.55% (-1.6%)
6% less funds holding
Funds holding: 32 → 30 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$73.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.31K |
| 4 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$234 |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$203 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$156K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.22K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.5K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$224 |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$224 |
IBIO Hedge Fund Activity: Q4 2024 in Review
30 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q4 2024, worth a combined $6.4M — up 11% from $5.79M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IBIO and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $95.4K. The largest seller was ADAR1 Capital Management, cutting an estimated $156K.
- 30 institutional investors held iBio (IBIO) as of Q4 2024, down from 32 in Q3 2024.
- Funds reported $6.4M of iBio stock for Q4 2024, up 11% quarter-over-quarter.
- 1 fund opened new iBio positions in Q4 2024 and 3 closed out, a net change of -2 holders.
- The largest iBio buyer in Q4 2024 was Vanguard Group, an estimated $95.4K added.
- The largest iBio seller in Q4 2024 was ADAR1 Capital Management, an estimated $156K sold.
Based on aggregated 13F filings for Q4 2024.